Abstract Objective Scleroderma renal crisis (SRC) is associated with high morbidity and mortality and there remain unmet needs regarding early identification and treatment. We aimed to assess risk factors for and the outcomes of SRC at a large Australian tertiary hospital. Methods Seventeen incident SRC cases were diagnosed between 2012–2022. Demographic, systemic sclerosis (SSc) manifestations, and treatment data were extracted. Using data from the Australian Scleroderma Cohort Study (ASCS) (n = 483), logistic regression analysis was performed to identify risk factors for SRC. Results The prevalence of SRC was 3.52%. The median SSc disease duration at SRC onset was 2 (IQR 1–4) years. Peak creatinine occurred at a median of 11 (IQR 5–14) days post-SRC diagnosis with a median peak creatinine of 144 (IQR 86–306) µmol/l. Nine (52.94%) SRC patients had evidence of acute neurologic and/or cardiac complications. Acute hemofiltration was required in 3 (17.65%) patients. Over the follow-up period, 7 (41.18%) SRC patients died 2.75 (IQR 0.74–7.25) years after SRC onset. Patients with SRC were more likely to be male (OR 9.73, 95%CI 3.57–26.56), have diffuse disease (OR 23.16, 95%CI 5.22–102.80), and have antibodies to Scl70 (OR 3.34, 95%CI 1.24–9.04) or RNA polymerase III (RNAPIII) (OR 5.15, 95%CI 1.91–13.89). Conclusion SRC is an uncommon manifestation, but outcomes remain poor. A significant proportion of patients presenting with SRC in Australia are positive for Scl70 or RNAPIII antibody. Despite relatively low peak serum creatinine and rates of renal replacement therapy, SRC was still associated with significant mortality.